ALLO(Allogene Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $114.09M | $156.00K | $95.00K | $22.00K | $0 |
| 毛利润 | — | — | — | — | — |
| 营业利润 | −$180.19M | −$335.54M | −$327.74M | −$273.20M | −$209.31M |
| 净利润 | −$182.05M | −$340.41M | −$327.26M | −$257.59M | −$190.89M |
| 经营现金流 | −$184.81M | −$220.52M | −$237.73M | −$200.30M | −$149.25M |
| 自由现金流 | −$206.26M | −$225.71M | −$239.25M | −$200.99M | −$149.63M |
| 摊薄每股收益 | $-1.34 | $-2.38 | $-2.09 | $-1.32 | $-0.87 |